SDC1 and plasma cell myeloma: Combining anti-CD138 antibodies with proteosome inhibitors (bortezomib) or immune modulatory drugs (IMiDs) such as lenalidomide, creates a potentially powerful new strategy to fight myeloma, boosting the immune system’s ability to engulf and destroy both sensitive and resistant cancer cells (53).